Compare iShares Core High Dividend ETF (HDV) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core High Dividend ETF vs IDEXX Laboratories, Inc. — how do they compare? iShares Core High Dividend ETF trades at $28.75 (market cap $14.68B), while IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 2.8× iShares Core High Dividend ETF's market cap, and iShares Core High Dividend ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core High Dividend ETF for 117 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| HDV | IDXX | |
|---|---|---|
Market Cap | $14.68B | $40.43B |
Volume | 2,925,562 | 692,164 |
52-Week High | $29.93 | $766.68 |
52-Week Low | $23.64 | $504.70 |
Typical Hold Time | 117 Days | 46 Days |
Sector | — | Health |
Enterprise Value | — | $41.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HDV (iShares Core High Dividend ETF) trades at $28.71, up 1.52% with a bullish technical signal. Recent sector rebalancing reduced healthcare exposure by nearly half while increasing energy, staples, and utilities, creating concentration risk with 62% in three sectors. The ETF yields approximately 3% but faces questions about whether this compensates for reduced diversification. Technical indicators show strong momentum with RSI at 77.74 suggesting potential overbought conditions.
The outlook remains cautiously optimistic given HDV's 2026 outperformance against the S&P 500, though the concentrated sector allocation and moderate yield present both opportunity and risk. Investors should weigh the fund's recent structural changes against its dividend income generation capabilities in a rising rate environment.
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
